DANOY Q1: Has $75M Recall Cost and ME Sales Dip Eased Headwinds?
Quarterly scorecard on Danone's infant formula recall expenses and Middle East revenue pressure from Iran conflict — the two metrics that define if profitability risks are fading.
Key Takeaways
Danone reported Q1 2026 results on April 21, with total revenue of $6.85 billion, down 2.1% YoY, including a 4.2% drop in infant nutrition to $1.15 billion and a 6% decline in Middle East sales tied to Iran disruptions. Recall-related costs hit $75 million, below the $100 million threshold for major concern, while margins compressed just 1.1 points without guidance cuts. These prints keep the headwind narrative alive but shy of breakdown levels, suggesting DANOY could stabilize if Q2 holds similar patterns — underperform versus staples peers only if declines accelerate. The thesis breaks if infant revenue rebounds above flat YoY or costs drop below $50 million by Q3 end.
Danone (DANOY) reported Q1 2026 earnings on April 21. Total revenue fell to $6.85 billion (-2.1% YoY, -0.8% constant currency), with infant nutrition at $1.15 billion (-4.2% YoY) and Middle East sales down 6% on supply strains from the Iran conflict. Recall remediation expenses totaled $75 million, contributing to a 110bps gross margin squeeze.
The two tracked metrics, this quarter
| Metric | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Infant Nutrition Revenue | $1.15B | $1.20B | -4.2% |
| Recall-Related Costs | $75M | $0 (pre-recall) | New $75M Charge |
Middle East sales (embedded in EMEA): Q1 2026 down 6% YoY, flagged in commentary as Iran-linked but stabilizing.
What the change tells us
Infant nutrition revenue's 4.2% YoY decline flirts with the >5% redline for heightened headwinds but stays in manageable territory, as management noted partial volume recovery in non-recall markets and no new regulatory drags; this ties directly to the material change rule, where crossing 5% would signal lost sales momentum and force consensus EPS cuts. Recall costs at $75 million landed under the $100 million flagpoint, covering remediation without fines, implying the operational hit is contained versus worst-case multi-quarter drains — a green light for now, though cumulative charges could still weigh if Q2 adds more.
Conclusion: the thread is still developing
Q1 metrics confirm ongoing pressure without triggering thesis-breaking escalation; Danone's full-year guidance holds steady, but the headwind watch persists as infant and ME trends bear watching.
What to watch in Q2 2026
Infant nutrition YoY growth above -5% (sustained flat target), recall costs under $50 million quarterly, and Middle East sales rebound to +2% organic — breaches below these reset the underperformance risk higher.